| Autor: |
Sulkowski, Parker L., Corso, Christopher D., Robinson, Nathaniel D., Scanlon, Susan E., Purshouse, Karin R., Bai, Hanwen, Yanfeng Liu, Sundaram, Ranjini K., Hegan, Denise C., Fons, Nathan R., Breuer, Gregory A., Yuanbin Song, Mishra-Gorur, Ketu, De Feyter, Henk M., de Graaf, Robin A., Surovtseva, Yulia V., Kachman, Maureen, Halene, Stephanie, Günel, Murat, Glazer, Peter M. |
| Předmět: |
|
| Zdroj: |
Science Translational Medicine; 2/1/2017, Vol. 9 Issue 375, p1-15, 15p, 6 Graphs |
| Abstrakt: |
The article presents a study that demonstrated mutant isocitrate dehydrogenase 1 (IDH1)-dependent poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitor sensitivity in a range of clinically relevant models, including primary patient-derived glioma cells in culture and genetically matched tumor xenografts in vivo. Topics discussed include findings providing the basis for a possible therapeutic strategy exploiting the biological consequences of mutant IDH. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
